Breast Cancer
Conditions
Interventions
Single arm:dihydroartemisinin was administered during radiotherapy
Sponsors
Yunnan Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. voluntarily participate and sign the informed consent form in person; 2. Chinese women aged > 18 to =70, predicted survival longer than 3 months; 7. to obtain the results of ER, PR, HER2 and Ki-67 of primary breast lesions; 8. Women of child-bearing age, should use contraception for at least one month before screening and commit to use contraception for the entire duration of the study and for a specified period after the study.
Exclusion criteria
Exclusion criteria: 1. patients with leptomeningeal metastasis considered by imaging; 2. the number of intracranial metastases > 10; 3. pregnant or lactating women; 4. Patients with serious non-neoplastic medical complications, which may affect the implementation of radiotherapy; 5. liver and kidney dysfunction > 1.5 times normal value, as assessed by the investigator, affecting drug users; 6. allergic or intolerant to DHA. 7. history of malignant tumors within the past 5 years (excluding previous lobular carcinoma in situ, skin basal cell carcinoma, skin carcinoma in situ, and cervical carcinoma in situ); 8. patients unable or unwilling to receive radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intracranial control rates at 6 months, 1 year, and 2 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| There was no extracranial distant metastasis rate at 6 months, 1 year, and 2 years;Intracranial recurrence-free survival at 6 months, 1 year, and 2 years;6 months, 1 year, and 2 years overall survival;Acute and chronic radiation-related adverse reactions;Drug-related adverse reactions;Quality of Life Evaluation; | — |
Countries
China
Contacts
Public ContactLi Wenhui
Yunnan Cancer Hospital
Outcome results
None listed